Gastroenterology and Hepatology Department

National University Hospital

Stomach Cancer

COVID-19

Kidney Diseases

Gastrointestinal Cancer

Adenocarcinoma Of Esophagus

Liver Cancer

Dyssomnias

Pancreatic Cancer

Cholangiocarcinoma

Parasomnias

Obeldesivir

Cabotamig

ARB202

Mezagitamab

Arbele

Gilead Sciences

National University Health System (NUHS)

Takeda

National University of Singapore

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study aims to find out:

1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker.
2. To find out how study drug is broken down in the body
3. To know the effects of the study drug on the tumor.

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

National University Hospital | Gastroenterology and Hepatology Department

Site insights

Work at this site?

Active trials

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Trial sponsors